Biggest lobbying interests buck trend with higher 2024 spending
But tallying up the top 10’s activity is still useful in measuring broad industry trends, since it demonstrates the relative firepower aimed at influencing policy.
Search Roll Call
Search the Roll Call archive by keyword, date, Congress, section, or tags.
2 results for "(S)-1-hydroxy-(S)-2-methylhexane"
Dual court rulings throw confusion into abortion drug debate
Bob Latta, R-Ohio, have introduced a bill (S 95, HR 427) that would rescind FDA approval of mifepristone and led a letter to FDA Commissioner Robert Califf also asking for FDA to act. Rep.